A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

← catalyst calendar

NCT04752774 · readout in 953 d

Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

240estimated

Sites

Countries

Austria, Bulgaria, Czechia +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-04-29

actual

When the study began enrolling

Primary completion

2029-03-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-03-30

estimated

The whole study's end, after follow-up

First posted

2021-02-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Spasticity

Interventions

Biological: Corabotase — also filed as IPN10200
Drug: Placebo
Biological: Dysport

Primary outcomes

what the primary-completion date above is the date OF

Percentage of participants with treatment emergent adverse events (TEAEs).

measured From baseline until the end of study (9 months)

Percentage of participants with adverse events of special interest (AESI).

measured From baseline until the end of study (9 months)

Change from baseline in vital sign parameter (blood pressure)

measured 9 months

Change from baseline in vital sign parameter (Heart rate)

measured 9 months

Change from baseline in clinical laboratory test results.

measured 9 months

Presence of IPN10200 and BoNT-A antibodies (binding and neutralising)

measured From baseline until the end of study (9 months)

Change from baseline in physical examination findings.

measured 9 months

Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed